$1.76 EPS Expected for Express Scripts (ESRX) This Quarter

Analysts expect Express Scripts (NASDAQ:ESRX) to announce earnings per share of $1.76 for the current fiscal quarter, Zacks reports. Eleven analysts have provided estimates for Express Scripts’ earnings. The highest EPS estimate is $1.77 and the lowest is $1.74. Express Scripts posted earnings per share of $1.33 in the same quarter last year, which would suggest a positive year-over-year growth rate of 32.3%. The business is expected to issue its next quarterly earnings report after the market closes on Monday, April 23rd.

On average, analysts expect that Express Scripts will report full-year earnings of $9.33 per share for the current year, with EPS estimates ranging from $9.11 to $9.41. For the next year, analysts forecast that the business will post earnings of $10.11 per share, with EPS estimates ranging from $9.48 to $10.50. Zacks’ earnings per share averages are a mean average based on a survey of research firms that follow Express Scripts.

How to Become a New Pot Stock Millionaire

Express Scripts (NASDAQ:ESRX) last issued its quarterly earnings results on Tuesday, February 27th. The company reported $2.16 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.09 by $0.07. The firm had revenue of $25.38 billion for the quarter, compared to analysts’ expectations of $25.07 billion. Express Scripts had a return on equity of 25.19% and a net margin of 4.51%. Express Scripts’s revenue was up 2.1% on a year-over-year basis. During the same quarter last year, the business posted $1.88 EPS.

A number of equities research analysts have commented on ESRX shares. Needham & Company LLC restated a “hold” rating on shares of Express Scripts in a research report on Thursday, December 21st. SunTrust Banks set a $86.00 price objective on Express Scripts and gave the stock a “buy” rating in a research report on Thursday, December 21st. BidaskClub upgraded Express Scripts from a “buy” rating to a “strong-buy” rating in a research report on Friday, December 22nd. Evercore ISI started coverage on Express Scripts in a research report on Thursday, January 4th. They set an “in-line” rating and a $78.00 price objective for the company. Finally, Robert W. Baird restated a “buy” rating and set a $92.00 price objective (up from $81.00) on shares of Express Scripts in a research report on Tuesday, January 9th. Three equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating and five have assigned a buy rating to the company. Express Scripts currently has an average rating of “Hold” and an average target price of $81.97.

In other news, VP Everett Neville sold 4,895 shares of Express Scripts stock in a transaction dated Thursday, March 1st. The stock was sold at an average price of $75.26, for a total transaction of $368,397.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Christine Houston sold 19,889 shares of Express Scripts stock in a transaction dated Thursday, March 15th. The shares were sold at an average price of $76.69, for a total value of $1,525,287.41. The disclosure for this sale can be found here. 0.79% of the stock is owned by insiders.

Several institutional investors have recently made changes to their positions in ESRX. Swedbank acquired a new stake in Express Scripts in the 4th quarter worth approximately $111,016,000. Polianta Ltd lifted its holdings in Express Scripts by 38.9% in the 4th quarter. Polianta Ltd now owns 20,700 shares of the company’s stock worth $1,545,000 after purchasing an additional 5,800 shares during the last quarter. Leucadia National Corp acquired a new stake in Express Scripts in the 4th quarter worth approximately $567,000. Xact Kapitalforvaltning AB lifted its holdings in Express Scripts by 5.2% in the 4th quarter. Xact Kapitalforvaltning AB now owns 102,730 shares of the company’s stock worth $7,668,000 after purchasing an additional 5,123 shares during the last quarter. Finally, Glenmede Trust Co. NA lifted its holdings in Express Scripts by 1.6% in the 4th quarter. Glenmede Trust Co. NA now owns 422,156 shares of the company’s stock worth $31,508,000 after purchasing an additional 6,448 shares during the last quarter. Institutional investors and hedge funds own 89.31% of the company’s stock.

Shares of NASDAQ ESRX opened at $71.99 on Friday. Express Scripts has a one year low of $55.80 and a one year high of $85.07. The stock has a market cap of $40,216.86, a price-to-earnings ratio of 10.14, a price-to-earnings-growth ratio of 0.88 and a beta of 0.99. The company has a debt-to-equity ratio of 0.83, a current ratio of 0.67 and a quick ratio of 0.55.

Express Scripts announced that its Board of Directors has initiated a stock buyback plan on Monday, December 18th that permits the company to buyback 45,000,000 shares. This buyback authorization permits the company to repurchase shares of its stock through open market purchases. Stock buyback plans are often an indication that the company’s board of directors believes its shares are undervalued.

TRADEMARK VIOLATION WARNING: “$1.76 EPS Expected for Express Scripts (ESRX) This Quarter” was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.chaffeybreeze.com/2018/04/17/1-76-eps-expected-for-express-scripts-esrx-this-quarter.html.

About Express Scripts

Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services.

Get a free copy of the Zacks research report on Express Scripts (ESRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Express Scripts (NASDAQ:ESRX)

Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply